Brief: Dermata Therapeutics To Begin Enrolling Patients In Dmt310 Phase 3 Acne Clinical Program
16/11/2023 13:39
Nov 16 (Reuters) - Dermata Therapeutics Inc DRMA.O :
* DERMATA THERAPEUTICS INC: TO BEGIN ENROLLING PATIENTS IN
DMT310
PHASE 3 ACNE CLINICAL PROGRAM IN DEC BASED ON AGREEMENT WITH FDA
ON PHASE 3 PROTOCOLS
* DERMATA THERAPEUTICS INC: TOPLINE RESULTS FROM STAR-1
CLINICAL
TRIAL EXPECTED IN Q1 2025
Further company coverage: DRMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dermata Therapeutics
See all newsNASDAQ RESUMED AT 10:31 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview